IDH mutations in glioma and acute myeloid leukemia

Lenny Dang(Agios Pharmaceuticals (United States)), Shengfang Jin(Agios Pharmaceuticals (United States)), Shinsan M. Su(Agios Pharmaceuticals (United States))
Trends in Molecular Medicine
August 6, 2010
10.1016/j.molmed.2010.07.002
Cited by 374

Abstract

Related Papers

p53, the Cellular Gatekeeper for Growth and Division
Arnold J. Levine|Cell|1997|7.7k
Targeting HIF-1 for cancer therapy
Gregg L. Semenza|Nature reviews. Cancer|2003|6.7k
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward, Jay Patel, David R. Wise et al.|Cancer Cell|2010|2k
Glioma-Derived Mutations in <i>IDH1</i> Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao, Yan Lin, Wei Xu et al.|Science|2009|1.1k
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
David Capper, Susanne Weißert, Jörg Balß et al.|Brain Pathology|2009|523